RASSF10 is epigenetically silenced and functions as a tumor suppressor in gastric cancer

Biochemical and Biophysical Research Communications

Volumn 432, Issue 4, 2013, Pages 632-637

  Wei, Ziran ^a   Chen, Xia ^b   Chen, Ji ^a   Wang, Weimin ^a   Xu, Xudong ^b   Cai, Qingping ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b The Central Hospital of Minhang District   (China)

Author keywords

Gastric cancer; RASSF10; Tumor suppressor

Indexed keywords

BETA CATENIN; CYCLIN D1; CYCLIN E1; CYCLINE; HERMES ANTIGEN; MYC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; RAS ASSOCIATION DOMAIN FAMILY 10 PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR 4; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; GENE OVEREXPRESSION; GENE SILENCING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN METHYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; TUMOR XENOGRAFT;

BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; WNT PROTEINS; WNT SIGNALING PATHWAY;

ANIMALIA;

EID: 84875521750     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.02.033     Document Type: Article

References (30)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
3. Vogiatzi P., Vindigni C., Roviello F., Renieri A., Giordano A. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. J. Cell. Physiol. 2007, 211:287-295.
4. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
5. Byun D.S., Lee M.G., Chae K.S., Ryu B.G., Chi S.G. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res. 2001, 61:7034-7038.
6. Satoh A., Toyota M., Itoh F., Sasaki Y., Suzuki H., Ogi K., Kikuchi T., Mita H., Yamashita T., Kojima T., Kusano M., Fujita M., Hosokawa M., Endo T., Tokino T., Imai K. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res. 2003, 63:8606-8613.
7. Miotto E., Sabbioni S., Veronese A., Calin G.A., Gullini S., Liboni A., Gramantieri L., Bolondi L., Ferrazzi E., Gafà R., Lanza G., Negrini M. Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. Cancer Res. 2004, 64:8156-8159.
8. Wang Y., Li J., Cui Y., Li T., Ng K.M., Geng H., Li H., Shu X.S., Li H., Liu W., Luo B., Zhang Q., Mok T.S., Zheng W., Qiu X., Srivastava G., Yu J., Sung J.J., Chan A.T., Ma D., Tao Q., Han W., 1 CMTM3 located at the critical tumor suppressor locus 16q22, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis Cancer Res. 2009, 69:5194-5201.
9. Akino K., Toyota M., Suzuki H., Imai T., Maruyama R., Kusano M., Nishikawa N., Watanabe Y., Sasaki Y., Abe T., Yamamoto E., Tarasawa I., Sonoda T., Mori M., Imai K., Shinomura Y., Tokino T. Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer. Cancer Sci. 2007, 98:88-95.
10. Kaneda A., Kaminishi M., Yanagihara K., Sugimura T., Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res. 2002, 62:6645-6650.
11. Avruch J., Xavier R., Bardeesy N., Zhang X.F., Praskova M., Zhou D., Xia F. Rassf family of tumor suppressor polypeptides. J. Biol. Chem. 2009, 284:11001-11005.
12. Richter A.M., Pfeifer G.P., Dammann R.H. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim. Biophys. Acta 2009, 1796:114-128.
13. Sherwood V., Recino A., Jeffries A., Ward A., Chalmers A.D. The N-terminal RASSF family: a new group of Ras-association domain-containing proteins, with emerging links to cancer formation. Biochem. J. 2009, 425:303-311.
14. Underhill-Day N., Hill V., Latif F. N-terminal RASSF family: RASSF7-RASSF10. Epigenetics 2011, 6:284-292.
15. Dammann R., Yang G. Pfeifer GP, Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res. 2001, 61:3105-3109.
16. Akino K., Toyota M., Suzuki H., Mita H., Sasaki Y., Ohe-Toyota M., Issa J.P., Hinoda Y., Imai K., Tokino T. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 2005, 129:156-169.
17. Maruyama R., Akino K., Toyota M., Suzuki H., Imai T., Ohe-Toyota M., Yamamoto E., Nojima M., Fujikane T., Sasaki Y., Yamashita T., Watanabe Y., Hiratsuka H., Hirata K., Itoh F., Imai K., Shinomura Y., Tokino T. Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis 2008, 29:1312-1318.
18. Lee C.K., Lee J.H., Lee M.G., Jeong S.I., Ha T.K., Kang M.J., Ryu B.K., Hwangbo Y., Shim J.J., Jang J.Y., Lee K.Y., Kim H.J., Chi S.G. Epigenetic inactivation of the NORE1 gene correlates with malignant progression of colorectal tumors. BMC Cancer 2010, 10:577.
19. Hesson L.B., Dunwell T.L., Cooper W.N., Catchpoole D., Brini A.T., Chiaramonte R., Griffiths M., Chalmers A.D., Maher E.R., Latif F. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol. Cancer 2009, 8:42-52.
20. Hill V.K., Underhill-Day N., Krex D., Robel K., Sangan C.B., Summersgill H.R., Morris M., Gentle D., Chalmers A.D., Maher E.R., Latif F. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene 2011, 8:978-989.
21. Schagdarsurengin U. Richter AM, Wohler C, Dammann RH, Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics 2009, 4:571-576.
22. Dansranjavin T., Wagenlehner F., Gattenloehner S., Steger K., Weidner W., Dammann R., Schagdarsurengin U. Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma. Prostate 2012, 72:1550-1558.
23. Jin H., Wang X., Ying J., Wong A.H., Cui Y., Srivastava G., Shen Z.Y., Li E.M., Zhang Q., Jin J., Kupzig S., Chan A.T., Cullen P.J., Tao Q. Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc. Natl. Acad. Sci. USA 2007, 104:12353-12358.
24. Polakis P. Wnt signaling and cancer. Genes Dev. 2000, 14:1837-1851.
25. Peifer M., Polakis P. Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science 2000, 287:1606-1609.
26. Lustig B., Behrens J. The Wnt signaling pathway and its role in tumor development. J. Cancer Res. Clin. Oncol. 2003, 129:199-221.
27. Sansom O.J., Meniel V.S., Muncan V., Phesse T.J., Wilkins J.A., Reed K.R., Vass J.K., Athineos D., Clevers H., Clarke A.R. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007, 446:676-679.
28. He T.C., Chan T.A., Vogelstein B., Kinzler K.W. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999, 99:335-345.
29. Kanwar S.S., Yu Y., Nautiyal J., Patel B.B., Majumdar A.P. The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol. Cancer 2010, 9:212.
30. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.